北京君正(300223.SZ):紹興韋豪的持股比例升至5%
格隆匯6月13日丨北京君正(300223.SZ)公佈,紹興韋豪企業管理諮詢合夥企業(有限合夥)(“紹興韋豪”)於2021年10月參與認購公司向特定對象發行股票,發行完成後,紹興韋豪持有公司530.0183萬股股份,持股比例為1.10%。2022年3月24日至2022年5月19日期間,紹興韋豪通過集中競價方式累計增持公司1860.4904萬股股份,增持完成後累計持有公司2390.5087萬股股份,持股比例為4.96%。
近日,紹興韋豪通過證券交易所集中競價交易增持公司17.34萬股股份,增持後累計持有公司2407.8487萬股股份,佔公司總股本的5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.